CA-BATTERY-SHOW/EV-TECH
27.4.2021 12:04:13 CEST | Business Wire | Press release
The Battery Show & EV Tech Europe Digital Days , a three-day digital event, strategically scheduled for 18-20 May to connect and educate industry professionals during a time of immense disruption via technical sessions, panels, networking opportunities, and digital sourcing, today announced the second raft of speakers confirmed to address the advanced battery and hybrid & electric vehicle (H/EV) tech community. Executives and senior-level experts from 3M, EnBW, McLaren Applied, Punch Powertrain, Renault, among many others, will present novel solutions and lead technical demonstrations that address the industry's leading challenges. The online conference will run adjacent to the digital exhibition floor that features hundreds of leading companies including Parker/LORD, Siemens, and TE Connectivity.
Registration for the digital conference and exhibition is open to attendees and press:
As the effects of the ongoing COVID-19 pandemic continue to impact grid storage, battery materials, battery-powered electric vehicles, and manufacturer supply chains, the European region is presented with unprecedented stressors amid exceptional market acceleration. Speaking to the importance and timeliness of the event, James Frith, Head of Energy Storage at Bloomberg New Energy Finance and chair of the keynote panel “Meeting Demand for EV Battery Production in Europe; The Rise of the Giga Factory,” said: "The European battery manufacturing industry has been turned on its head over the last three years, going from almost non-existent to the second largest market globally. The Digital Days event will be the perfect opportunity to find out how the companies at the heart of this change envisage the next decade."
"At the rate the advanced battery and H/EV tech sectors are progressing in the European region and the number of obstacles that require an immediate solution, we felt it was critical to orchestrate industry connection before our next in-person event in November," said Rob Shelton, group event director, The Battery Show & EV Tech Europe Digital Days, Informa Markets. "The level of support for the upcoming digital event permeates all corners of the industry and is a clear indicator of the battery and H/EV tech market's fortitude and future advancement."
Featured conference content includes:
Tuesday 18 May
EV Forecasts: 2020 Summary of European EV Market Expansion and its Implications on Battery Demand
Speaker: Viktor Irle, Co-Founder & Market Analyst, EV Volumes
Latest Developments in EV Architectures: Determining the Optimum Level of Hybridization versus Societal, Environmental, and Economic Benefits
Speaker: Marcin Seredynski, Head of Innovation and Research, E-Bus Competence Centre
Race to Road Debate: Examining Formula E & Hyper Car Architectures and How they Can be Adapted for the Mass Market EV
Moderator: Luke Gear, Technology Analyst, IDTechEx
- Angus Lyon, Director, Rockfort Engineering
- Yu Merla, Principal Engineer - Advanced Battery Projects, Williams Advanced Engineering
- Wasim Sarwar, Head of Research and Advanced Engineering, Rimac Automobil
Wednesday 19 May
EV Technical Session: The Role of Electric Vehicles in the Energy Transition
Speaker: Jeremy Parkes, Global Business Lead - Electric Vehicles, DNV
Keynote (Open to All) – Leaders Panel: Meeting Demand for EV Battery Production in Europe; the Rise of the Giga Factory
Moderator: James Frith, Senior Energy Storage Analyst, Bloomberg New Energy Finance
- Benoit Lemaignan, CEO, Verkor
- Kai-Uwe Wollenhaupt, President Europe & Vice President, SVOLT Energy Technology Company Ltd
- Sebastian Wolf, Sr Director EU Operations and Managing Director, Farasis Energy Europe
- Gery Bonduelle, SVP Sales, Freyr
- Allan Paterson, CTO, Britishvolt
Electric Motor Development: Faster Charging, Higher Efficiency, Longer Range: The next Step in Electrification
Steve Lambert, Head of Electrification, McLaren Applied
Electric Powertrain: Developing High-Speed Electric Drive Unit for the Next Generation
Speaker: Henrik Dhejne, Product Line Manager - Passenger Car Transmissions, electrified Transmission & e-Axle, AVL
Thursday 20 May
EV Technical Session: State of the art Electric Track Drive for Medium & Heavy-Duty Machines
Speaker: Massimo Palomba, Global Sales Manager E-Mobility, Bonfiglioli Mobility & Wind Industries, Bonfiglioli Spa
EV Technical Session: HEV Battery Design; Should it be for Second Life or Easy to Recycle?
Speaker: Paweł Swoboda, Business Development Manager, BMZ Poland
Electric Buses: If 70% Of EV Cost is in The Battery… How Can You Reduce the Cost of Electrification?
Speaker: Manos Polioudis, Head of Powertrain Engineering, Arrival
For the full The Battery Show & EV Tech Europe Digital Days conference agenda, please visit here .
Follow The Battery Show & EV Tech Europe Digital Days on social media: #TheBatteryShow
About Informa Markets – Engineering:
Informa Markets' Engineering portfolio is the leading B2B event producer, publisher, and digital media business for the world's $3-trillion advanced, technology-based manufacturing industry. Our print and electronic products deliver trusted information to the engineering market and leverage our proprietary 1.3-million-name database to connect suppliers with buyers and purchase influencers. We produce more than 50 events and conferences in a dozen countries, connecting manufacturing professionals from around the globe. The Engineering portfolio is organized by Informa, the world's leading exhibitions organizer that brings a diverse range of specialist markets to life, unlocking opportunities and helping them to thrive 365 days of the year. For more information, please visit www.informamarkets.com .
About Informa Markets
Informa Markets creates platforms for industries and specialist markets to trade, innovate and grow. Our portfolio is comprised of more than 550 international B2B events and brands in markets including Engineering, Healthcare & Pharmaceuticals, Infrastructure, Construction & Real Estate, Fashion & Apparel, Hospitality, Food & Beverage, and Health & Nutrition, among others. We provide customers and partners around the globe with opportunities to engage, experience and, do business through face-to-face exhibitions, specialist digital content and, actionable data solutions. As the world's leading exhibitions organizer, we bring a diverse range of specialist markets to life, unlocking opportunities and helping them to thrive 365 days of the year. For more information, please visit www.informamarkets.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210427005048/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Azafaros to Present at BIO International Convention 202615.6.2026 07:00:00 CEST | Press release
Azafaros, a private company building a portfolio to become a leader in lysosomal storage disorders (LSDs), focused on addressing neurological symptoms, today announced that it will present at the 2026 BIO International Convention taking place in San Diego, USA, from June 22-25. The company’s presentation is scheduled for Monday, June 22 at 4:30 PM in Theater 4. The presentation will highlight Azafaros’ progress in developing nizubaglustat, its lead investigational compound for the treatment of rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses (GM1/GM2) and Niemann-Pick type C disease (NPC). Nizubaglustat is currently in two Phase 3 registrational studies (NAVIGATE) treating patients with GM1/GM2 and NPC and expects to report topline data from the studies in 2028. “BIO provides an important opportunity to update our progress as we continue advancing nizubaglustat through late-stage clinical development,” said Stefano Portolano, CEO at A
Teledyne FLIR Defense Launches Black Recon™ Autonomous Micro-Drone15.6.2026 06:05:00 CEST | Press release
Autonomous launch, recovery, and recharge from military vehicles and fixed installations; Three-drone rotation provides persistent surveillance and real-time targeting data in contested environments Teledyne FLIR Defense, part of Teledyne Technologies Incorporated (NYSE: TDY), today announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone system that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260614388428/en/ Teledyne FLIR Defense announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. Black Recon allows crews to launch, operate, recover, and recharge up to three UAS without leaving their platform, reducing operator risk. Designed for vehicle integrati
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release
REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release
In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release
- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom